Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
NCT07005180
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Parkinson Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 40 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Last updated on ClinicalTrials.gov
- September 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- The Parkinson's & Movement Disorder Institute · Fountain Valley, CA
Florida · 1
- University of Florida · Gainesville, FL
Michigan · 1
- Quest Research Institute · Farmington Hills, MI
New York · 1
- Weill Cornell Medical College · New York, NY
Washington · 1
- Inland Northwest Research · Spokane, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.